Cargando…
Inhibition of SGLT2 Preserves Function and Promotes Proliferation of Human Islets Cells In Vivo in Diabetic Mice
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used for the treatment of diabetes. This study examines the effects of dapagliflozin on human islets, focusing on alpha and beta cell composition in relation to function in vivo, following treatment of xeno-transplanted diabetic mi...
Autores principales: | Karlsson, Daniel, Ahnmark, Andrea, Sabirsh, Alan, Andréasson, Anne-Christine, Gennemark, Peter, Sandinge, Ann-Sofie, Chen, Lihua, Tyrberg, Björn, Lindén, Daniel, Sörhede Winzell, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868601/ https://www.ncbi.nlm.nih.gov/pubmed/35203411 http://dx.doi.org/10.3390/biomedicines10020203 |
Ejemplares similares
-
Inhibition of the prostaglandin D(2)–GPR44/DP2 axis improves human islet survival and function
por: Abadpour, Shadab, et al.
Publicado: (2020) -
Disturbed α-Cell Function in Mice with β-Cell Specific Overexpression of Human Islet Amyloid Polypeptide
por: Ahrén, Bo, et al.
Publicado: (2008) -
The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis
por: Wallenius, Kristina, et al.
Publicado: (2022) -
Secretagogin is increased in plasma from type 2 diabetes patients and potentially reflects stress and islet dysfunction
por: Hansson, Sara F., et al.
Publicado: (2018) -
Input estimation for drug discovery using optimal control and Markov chain Monte Carlo approaches
por: Trägårdh, Magnus, et al.
Publicado: (2016)